Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ROBITZEK, E. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ROBITZEK, E. H.
(Chest. 1956;29:174-186.)
© 1956 American College of Chest Physicians

The Selection of Anti-Microbial Drugs for Patients of Different Categories

EDWARD H. ROBITZEK M.D., F.C.C.P.1

1 The Medical Service, Sea View Hospital.

1. Tuberculosis therapy has been complicated rather than simplified by the introduction of newer effective drugs.

2. Omitting the sulphones (for which there has been some recent renewal of interest) and the semicarbazones, the important drugs are isoniazid, streptomycin and PAS in various combinations.

3. Potentially important are pyrazinamide and oxytetracycline.

4. Less effectual against the tubercle bacillus but with special fields of usefulness are iproniazid and viomycin.

5. Of uncertain usefulness are salts of isoniazid and chemical conjugations between streptomycin and isoniazid and PAS or AS and isoniazid.

6. Still under investigation but immensely interesting is Cycloserine.®

7. Choice of drug regimens depends upon initial evaluation of the patient, estimation of sensitivities and minute knowledge of the history of the disease in the given patient.

8. Drug regimens should always include isoniazid unless allergy or toxicity rule otherwise.

9. Minimal lesions call for concurrent therapy.

10. Protracted disease calls for consecutive therapy.

11. Therapy should be continued for one to one and a half years excepting in special instances, such as the post-surgery patient or the recent primary when duration of therapy may be considerably less.

12. Pleural effusions, presumed tuberculous, call for isoniazid or isoniazid plus PAS therapy.

13. Miliary tuberculosis requires combined therapy, one of the members of which must always be isoniazid.

14. Ambulatory therapy is feasible in many instances but is allowable only after careful analysis of the case.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1956 by the American College of Chest Physicians.